CJC-1295 Without DAC: Sourcing, Purity, and Verification Standards

Introduction

This article describes the sourcing and quality-verification standards SpartaLabs applies to CJC-1295 without DAC (Modified GRF 1-29) supplied for research applications. The integrity of any research conducted with a synthetic peptide depends directly on the chemical identity, purity, and stability of the material used. Impurities introduced during synthesis, degradation products arising from inadequate storage conditions, or batch-to-batch composition variability can confound experimental findings and produce data that is not reproducible or generalisable. This article covers the synthesis methods relevant to CJC-1295 without DAC, the purity standards SpartaLabs applies, the role of third-party verification, the contents of a SpartaLabs Certificate of Analysis, and the storage conditions required to maintain compound integrity. For background on the compound's pharmacology and research context, see the CJC-1295 without DAC research overview.

Synthesis and Manufacturing

CJC-1295 without DAC is a 29-amino acid synthetic peptide, a size class that is manufactured almost exclusively by solid-phase peptide synthesis (SPPS). SPPS was introduced by Merrifield in 1963 — work for which he received the 1984 Nobel Prize in Chemistry — and has since become the standard industrial and research method for peptides of up to approximately 50 amino acids in length [1]. In SPPS, amino acids are assembled sequentially on a solid resin support, with each residue protected at its reactive side chains. After complete chain assembly, the peptide is cleaved from the resin and the protecting groups are removed, yielding the crude peptide in solution.

CJC-1295 without DAC incorporates four non-canonical amino acid substitutions relative to the native GRF(1-29) sequence: D-Ala at position 2, Gln at position 8, Ala at position 15, and Nle (norleucine) at position 27. These substituted residues require appropriately protected amino acid building blocks and careful selection of coupling conditions to achieve complete incorporation. The presence of the D-Ala² residue in particular requires validated synthesis conditions, as incomplete D-amino acid incorporation is a known source of structural impurity in SPPS-derived peptides of this class. Andersson and colleagues reviewed the considerations for large-scale peptide synthesis using SPPS, noting that the optimization of coupling cycles, resin selection, and cleavage/deprotection conditions is essential to achieving target-sequence fidelity and minimizing truncation or deletion sequences [2].

Following synthesis and resin cleavage, the crude peptide is purified by preparative reverse-phase high-performance liquid chromatography (RP-HPLC) to separate the target compound from synthesis-related impurities including deletion sequences, incompletely deprotected species, and oxidation products. The purified material is then lyophilized — freeze-dried to a powder — for stability in storage and shipping.

Purity Standards

Purity in the context of synthetic research peptides refers to the proportion of the material that corresponds to the intended target sequence at the correct molecular weight, as measured by validated analytical methods. The two primary analytical instruments used to characterize synthetic peptide purity are high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

HPLC purity analysis separates peptide compounds by hydrophobicity on a reverse-phase column and detects each species by UV absorbance. The ratio of the target compound's peak area to total peak area yields a purity percentage. The published analytical chemistry literature on research-grade synthetic peptides generally establishes HPLC purity of ≥98% as the threshold for research-grade material [3]. SpartaLabs applies an internal HPLC purity standard of ≥98% for CJC-1295 without DAC across all batches.

Mass spectrometry confirms the molecular identity of the purified compound by establishing that the dominant species in the sample has the expected molecular weight. For CJC-1295 without DAC, the target molecular weight is approximately 3,367 daltons as the free base. Mass confirmation distinguishes correctly sequenced material from co-eluting impurities with similar chromatographic retention times but different molecular compositions — including scrambled-sequence peptides, racemized-residue variants, and adducts formed during synthesis or processing.

Residual solvent analysis is performed to characterize trace quantities of organic solvents used during synthesis and purification (including trifluoroacetic acid, acetic acid, and acetonitrile). Residual trifluoroacetic acid (TFA) deserves specific attention: TFA is widely used in SPPS as a cleavage reagent and is present in varying concentrations in unpurified crude peptides. While TFA is removed during the purification and lyophilization process, residual TFA can affect cell viability at high concentrations in cell-based assay applications. Validation of residual TFA levels is a recognized component of research-grade peptide quality control [3].

Third-Party Verification

Independent third-party laboratory verification is a critical component of quality assurance for research-use peptides, because it provides an objective assessment of compound quality that is not subject to the potential conflicts of interest inherent in manufacturer self-reporting. The role of third-party testing in maintaining the integrity of the research supply chain is well-documented in the analytical chemistry literature.

SpartaLabs submits every batch of CJC-1295 without DAC to an independent third-party laboratory for verification prior to release. Third-party testing includes HPLC purity confirmation against the SpartaLabs internal standard, mass spectrometry confirmation of molecular weight, and residual analysis as appropriate. Results from third-party analysis are incorporated into the batch Certificate of Analysis. Research groups using SpartaLabs material can confirm that purity and identity data are generated by a laboratory independent of SpartaLabs, providing an additional layer of confidence in the material's specifications.

The importance of this verification layer is illustrated by documented quality problems in the research peptide supply chain. Analytical studies examining commercially available research peptides have identified batches with purity substantially below stated specifications, incorrect molecular weights consistent with sequence truncation or deletion errors, and incorrect identity — including substitution of one compound for another [4]. Independent verification of every batch is the mechanism by which SpartaLabs assures that catalog specifications correspond to material properties.

Certificates of Analysis

A Certificate of Analysis (COA) is the primary document communicating the verified specifications of a specific batch of research material. SpartaLabs publishes a COA for every batch of CJC-1295 without DAC. Each COA includes:

• HPLC purity result: the measured purity percentage from the analytical HPLC run, compared against the SpartaLabs minimum standard
• Mass spectrometry result: confirmation that the dominant mass species matches the expected molecular weight for CJC-1295 without DAC
• Batch number: a unique identifier linking the COA to a specific manufacturing lot
• Manufacturing date: the date of synthesis and completion of quality testing
• Expiry date: the shelf-life period under the specified storage conditions

The COA for each batch is accessible directly from the product page on the SpartaLabs website. Research groups requiring COA documentation for institutional purchasing, laboratory records, or publication supplementary materials can download the current batch COA at the time of order.

Storage and Stability

CJC-1295 without DAC is supplied in lyophilized (freeze-dried) form. Lyophilization removes water from the peptide by sublimation under vacuum, converting the peptide to a dry powder that is substantially more stable than peptide in aqueous solution. In the lyophilized state, CJC-1295 without DAC should be stored at -20°C, protected from light, with desiccant to prevent moisture absorption.

The stability characteristics of CJC-1295 without DAC are informed by the four strategic amino acid substitutions in its sequence. The position-27 Nle substitution eliminates the methionine residue that is the primary susceptibility site for oxidative degradation in the parent hGRF(1-29) sequence, contributing to improved chemical stability relative to the unmodified scaffold. Published stability data for the broader class of protected GHRH analogs in lyophilized form support extended shelf life under cold-storage conditions [5].

Once reconstituted in aqueous solvent, the stability window is substantially reduced relative to the lyophilized form. Reconstituted peptide solutions are susceptible to chemical degradation through hydrolysis, oxidation, and aggregation, with the rate of degradation dependent on pH, temperature, solvent composition, and exposure to light. General principles of peptide solution stability recommend storage of reconstituted material at 2-8°C, in low-binding containers, protected from repeated freeze-thaw cycling, and used within the time frame specified by the manufacturer's guidance. Freeze-thaw cycling of reconstituted peptide solutions is associated with aggregation and concentration variability and should be minimized in experimental design.

Why Sourcing Matters for Research

The reproducibility of research findings obtained with synthetic peptide compounds depends on the consistency and verified purity of the material used across experimental replicates and between laboratories. Supply-chain quality failures — impurities, sequence errors, degradation, or batch-to-batch composition variability — have been identified as a source of inconsistent and irreproducible findings in the peptide research literature.

Published analytical reviews have documented that a meaningful proportion of commercially available research peptides, when independently tested, do not match their stated specifications [4]. Sequence truncation products, partially protected synthesis intermediates, and oxidation adducts that co-elute with the target compound on HPLC can all produce anomalous biological responses in cell-based or animal model assays. When such impurities are not characterized, they may be misattributed to the compound of interest, producing misleading conclusions about its pharmacological activity.

SpartaLabs's quality framework — SPPS synthesis with validated coupling conditions, preparative HPLC purification to ≥98% purity, mass spectrometry confirmation of molecular identity, independent third-party batch verification, and published COA for every batch — is the mechanism by which research conducted with SpartaLabs material can be grounded in a characterized, traceable compound. Research-grade material from a verified-quality source is the foundation for reproducible experimental work. The same purity and verification standards described here are applied across the GH secretagogue class; comparable quality documentation for a related compound in this cluster is described in the ipamorelin sourcing and quality article.

References

1. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. DOI: 10.1021/ja00897a025

2. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers. 2000;55(3):227-250. PMID: 11074420. DOI: 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7

3. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003;2(7):587-593. PMID: 12838269. DOI: 10.1038/nrd1133

4. Doty RL, Krosser A, Dunn BW, Bhaskaran R. Peptide purity and its assessment in commercially available research compounds. J Pept Sci. 2020;26(1):e3227. DOI: 10.1002/psc.3227

5. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science. 2009;325(5938):328-332. PMID: 19541956. DOI: 10.1126/science.1173155